By Lexaria Bioscience Corp. on Thursday, 14 November 2019
Category: Pharmaceutical - BioTech

Lexaria Bioscience closes US$700,000 financing to fund research into DehydraTECH

viewLexaria Bioscience Corp.

The funds raised will go towards research and development of the company’s innovative DehydraTECH drug delivery system

Kelowna, BC-based Lexaria issued nearly 1.6 million units priced at US$0.45 per unit for total proceeds of US$699,410.25

() (OTCMKTS:LXRP) announced Thursday that it raised nearly US$700,000 via the first tranche of a private placement.

The funds raised will go towards research and development of the company’s innovative DehydraTECH drug delivery system as well as general working capital, it said in a statement.

Kelowna, BC-based Lexaria issued nearly 1.6 million units priced at US$0.45 per unit for total proceeds of US$699,410.25.

READ: Lexaria Bioscience recruits Evolution VC Partners founder Gregg Smith as advisor

Each unit consists of one share and one warrant exercisable at US$0.80 until November 13, 2020 and thereafter at US$1.20 for a one-year period, at which point the warrants will expire.

Lexaria said that US$200,000 will be used for research and development of DehydraTECH, with US$50,000 each being spent on sales and marketing and finance and legal fees.

An additional US$75,000 is earmarked for pursuing patent applications, while US$170,000 is set aside for general working capital and US$150,000 for administration costs.

The company paid a finder’s fee of nearly US$4,000 and issued 8,750 warrants exercisable under the same terms as the private placement.

Shares of Lexaria slipped 1.5% at C$0.66 and 3% at US$0.50 on OTC markets on Thursday morning.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

CSE:LXX

Market: CSE
Market Cap: $52.47 m
Follow

View company profile

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Most read

Buds & Duds: Cannabis stocks hold steady; Lexaria rises on amended agreement...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, inched 0.2% higher at 122.9 points. Elsewhere, the OTCQX Cannabis index lost 0.2% to 489.3 points. Buds today are Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), Curaleaf Holdings Inc...

1 week, 5 days ago

2 min read

Related Posts